Macroamylasemia Overview
Learn About Macroamylasemia
Macroamylasemia is the presence of an abnormal substance called macroamylase in the blood.
Macroamylase is a substance that consists of an enzyme, called amylase, attached to a protein. Because it is large, macroamylase is filtered very slowly from the blood by the kidneys.
Most people with macroamylasemia do not have a serious disease that is causing it, but the condition has been associated with:
- Celiac disease
- Lymphoma
- HIV infection
- Monoclonal gammopathy
- Rheumatoid arthritis
- Ulcerative colitis
Macroamylasemia does not cause symptoms.
Elisa Bannone practices in Verona, Italy. Ms. Bannone is rated as an Elite expert by MediFind in the treatment of Macroamylasemia. Her top areas of expertise are Macroamylasemia, Gastrointestinal Fistula, Acute Pancreatitis, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery.
Giampaolo Perri practices in Padova, Italy. Perri is rated as an Elite expert by MediFind in the treatment of Macroamylasemia. Their top areas of expertise are Macroamylasemia, Gastrointestinal Fistula, Pancreatic Cancer, Pancreaticoduodenectomy, and Pancreatectomy.
Froedtert Andthe Medical College Of Wisconsin Community Physicians Inc
Amy Miller is a primary care provider, practicing in Family Medicine in Germantown, Wisconsin. Dr. Miller is rated as a Distinguished provider by MediFind in the treatment of Macroamylasemia. Her top areas of expertise are Hypertension, Familial Hypertension, Glucocorticoid-Remediable Aldosteronism, High Cholesterol, and Fasciotomy. Dr. Miller is currently accepting new patients.
Summary: Our aim is to compare early versus late pancreatic stent placement in preventing PEP among patients with naive papilla. The EVL trial will provide essential answers regarding the optimal timing of prophylactic pancreatic stent placement in PEP prevention.All patients with difficult biliary cannulation undergoing endoscopic retrograde cholangiopancreatography (ERCP) with pancreatic guidewire-assist...
Summary: Recent evidence suggests that postoperative hyperamylasemia (POH) is a predictor of morbidity after pancreatectomy. This is based on the assumption that pancreatitis after pancreatectomy (PPAP) is a major trigger for the development of complications and is indicated by hyperamylasemia. Standardized prospective analysis and correlation with other laboratory parameters, hasn't been performed to date...
Published Date: December 31, 2023
Published By: Jenifer K. Lehrer, MD, Department of Gastroenterology, Aria - Jefferson Health Torresdale, Jefferson Digestive Diseases Network, Philadelphia, PA. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
Forsmark CE. Pancreatitis. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024:chap 130.
Siddiqi HA, Rabinowitz S, Axiotis CA. Laboratory diagnosis of gastrointestinal and pancreatic disorders. In: McPherson RA, Pincus MR, eds. Henry's Clinical Diagnosis and Management by Laboratory Methods. 24th ed. Philadelphia, PA: Elsevier; 2022:chap 23.
Vege SS. Acute pancreatitis. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management. 11th ed. Philadelphia, PA: Elsevier; 2021:chap 58.